Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma
Status:
Terminated
Trial end date:
2021-02-15
Target enrollment:
Participant gender:
Summary
This study will be conducted in adult participants diagnosed with NSCLC who have been
previously treated for a minimum of 12 weeks with any PD-1 or PD-L1 checkpoint inhibitor.
This is a phase 1b/2, multi-center, open label study designed to assess safety and
tolerability of grapiprant in combination with pembrolizumab, to determine the recommended
phase 2 dose (RP2D) with pembrolizumab, and to evaluate disease response with grapiprant
based on investigator assessments. Pharmacokinetics, pharmacodynamics and response biomarkers
will also be assessed.